PCT

greytoc

Lol - no - it's not some sort of tinfoil conspiracy. What you are likely seeing what is known as a MOO and/or LOO orders. If you look closely as other stocks, you will usually see spikes at the open and/or close. It's more common to see them at the close as a result of MOC and LOC orders as well as VWAP transactions that cause these imbalances. It's a lot rarer to see them on the open. In the past - these spikes at the open are usually because of crappy institutional brokers who are doing a crap job at transition servicing for their fund and asset manager customers. That said - I looked at PCT - I think you saw a data error. I don't see 4bn shares at the open. Acronyms if you are unfamiliar: VWAP = volume weighted average price MOO = market on open MOC = market on close LOC = limit on close LOO = limit on open

Newfoundfriend5

Sorry, PCT is the stock whose volume I was looking at.

No_Privacy_Anymore

$PCT can absolutely generate 5-10x in the next 2-3 years IMO. I just visited their factory and met with the CEO and CFO. I believe they have the holy grail of recycling polypropylene. https://www.reddit.com/r/PureCycle/s/WX2tUF0Uwz

Total_Schedule591

I like PCT as well

Xenonstrike

$PCT I can see 10x from these levels if they can execute. High risk though

Dangerous-Mouse-976

Buying Anebulo Pharmaceuticals ANEB. I think they delisted to see. I used Ai for my analysis. Let me know you thoughts. The valuation case: Independent professional fairness opinion from Houlihan Capital valued the company at $3.50 per share in July 2025. Current price $0.88 to $1.00 represents an 71 to 75% discount to that independent professional valuation. You’re buying a dollar for 25 to 29 cents. The insider conviction: Aron English and 22NW deployed over $23 million across five separate purchases with zero sells ever. His most recent deployment was $10 million at $0.99 in December 2024 — after the oral program pivot, after the going-private announcement, after bankers said institutional interest was zero. He bought anyway. Professional fund manager with fiduciary obligations doesn’t do that without specific reason to believe value will be realized. The conditional pharma thesis: The coordinated December 2024 package — commercial consultant confirmation, FDA pre-IND meeting, $10 million capital deployment, all simultaneously — strongly suggests specific conditional pharma interest requiring Phase 1 IV safety data as the triggering condition. You don’t assemble that package without a specific reason. The going-private timing: Delisted February 2026 immediately after JPMorgan Healthcare Conference January 2026. Cunningham almost certainly had confidential pharma conversations at JPMorgan. Form 15 filed within weeks creating complete information darkness protecting those conversations from disclosure. The timing is surgical not coincidental. No banker hired: Companies run formal M&A processes with investment bankers when they don’t know who their buyer is. Anebulo never hired an M&A banker. That suggests they already know who their buyer is and don’t need a competitive process. The science is real: Completed Phase 1 and Phase 2 oral with positive efficacy data permanently banked. Clean safety profile across 250 subjects. First-in-class CB1 antagonist mechanism with zero competition. Active Phase 1 IV study enrolling right now with August 2026 completion. FDA actively collaborating on development — unusual and valuable signal. Federal validation: NIDA awarded Year 1 and Year 2 grants totaling approximately $1.9 million. Federal agencies don’t fund research they don’t believe in. Independent scientific validation from the National Institutes of Health. FDA collaboration: FDA specifically proposed close ongoing collaboration to advance the pediatric program. That language — close ongoing collaboration — is unusual. FDA doesn’t say that casually. It signals genuine institutional interest in seeing this drug developed. The PRV pathway: Priority Review Voucher worth $150 million upon FDA approval of a pediatric indication before September 2029. A pharma acquirer who can execute Phase 2 IV and get approval before 2029 captures $150 million that partially or fully offsets their acquisition cost. The PRV makes the economics of buying Anebulo dramatically more attractive for the right acquirer. The commercial consultant validation: A top five pharmaceutical consulting firm — the same firms that advise major pharma companies on commercial decisions — evaluated the pediatric ACI indication and confirmed it as commercially viable. This isn’t Cunningham’s opinion. It’s independent professional validation that pharma BD teams can reference in their own internal approval processes. The board composition: Every board member has specific relevant experience. Cunningham — pharma deals at Icagen with Roche and Sanofi. Shah — Goldman, JPMorgan, Warburg, Sumitomo, Genentech. Lin — sold Ab Initio to Ligand himself. Aryeh — on Ligand board. Kupchyk — former FDA Associate Chief Counsel for Drugs. English — 22NW conviction buyer. Lawler — founder with skin in the game. This is not a passive board. It’s assembled specifically to execute a transaction. Nantahala held through everything: An independent institutional investor with 8.53% ownership held through the going-private drama, the tender offer disappointment, the delisting, and the Form 15. They filed a 13G at the moment of delisting confirming their continued ownership. Sophisticated institutional investors don’t hold through that level of corporate chaos without conviction in the underlying value. The oral program floor value: Even if the IV pediatric program never generates a transaction the oral Phase 2 data package, manufacturing process, patent estate, and FDA relationship support a floor acquisition value of $20 to $40 million — $0.50 to $1.00 per share. You’re buying the floor value with the IV pediatric program and PRV as free options. The patent estate: Three issued US patents plus six applications plus PCT filings covering methods of use, composition of matter, and delivery systems. Meaningful IP protection that transfers full value to any acquirer. Cash runway confirmed: $9 million cash plus $3 million loan facility as of December 31 2025. Management guidance says funded through at least February 2027. Phase 1 IV completes August 2026. Cash runway covers the critical data readout with months of buffer. The PRV deadline creates urgency: September 2029 sunset means a pharma acquirer must act relatively soon to capture the PRV value before the window closes. Every month of delay reduces the time available to complete Phase 2 IV and get FDA approval. The deadline creates negotiating urgency that works in English’s favor. The cannabis market is growing: Legal cannabis expanding globally. Higher potency products increasing ACI severity. More pediatric exposures as legalization spreads. The commercial opportunity English and the commercial consultant evaluated in 2024 is larger in 2026 and will be larger still in 2028 when a Phase 3 oral or Phase 2 IV could complete. The sophisticated buyer activity this week: 48,506 shares traded Friday alone. Consistent $1.00 price support all week. Algorithmic accumulation suggesting institutional or sophisticated capital. A fund potentially trying to accumulate below $1.00 with specific price discipline. Smart money finding the same thesis independently and deploying real capital. The information asymmetry: Post Form 15 Anebulo has zero disclosure obligations. Any pharma conversation, any LOI, any term sheet, any data room activity is completely invisible. A deal announcement could come with zero warning at any time. The upside is binary and sudden. You either miss it or you don’t. The risk reward at current prices: Cost $0.88 to $1.00. Houlihan fair value $3.50. Potential deal value $3.50 to $5.00. Downside in distressed wind down $0.20 to $0.25. Risk reward approximately 3 to 1 to 5 to 1 at current prices. The complete bull case in one sentence: A first-in-class clinical stage pharmaceutical asset with validated Phase 2 efficacy data, active Phase 1 IV trial, FDA collaboration, NIDA validation, PRV optionality, $3.50 independent professional valuation, 51% controlling insider with $23 million deployed and zero sells, conditional pharma interest suggested by coordinated corporate actions, and complete information darkness protecting confidential deal negotiations — all trading at $0.88 to $1.00 per share with a sophisticated fund potentially accumulating below $1.00 right now

Paul_Robert_

Was thinking of selling covered calls on PCT, but I backed out. Therefore it's not going to pump, and is probably a good candidate for covered calls 💀

the_mind_goblin1

TRADERS PRICE IN 50 PCT CHANCE OF FED RATE INCREASE BY OCT Excellent, it's priced in. Now we can pump.

EyeSea7923

Gotta do it for at least 12. It just doesn't saturate very fast. If you do the 12-16 wks and roll off, look up PCT (post cycle therapy). Dont forget some blood work.

ThinkingOfTheOldDays

long chemical companies too, and $PCT

DrSeuss1020

Market punished a lot of high beta names and PCT got extra punishment because they’re going a bit slower than many want. But they had I think 170 trials ongoing and the facility buildouts still look to be on track. Sucks to be down like 30% but I still see the vision

Callejon007

Looking at PCT, price too lowl

Low_Regret_2330

I think you are quoting results for BPL-3. The EMP-1 is a different drug. Emp = oral, treats social anxiety and depression. It is in phase 2 ( earlier than bpl3) and is performing as expected. This is a therapy-assisted treatment where drug has all the good feels from mdma, but none of the visuals. BPL3-nasal spray, phase 2b, fastracked by FDA. Patient takes this in a supervised setting (dr. Office). Patient experiences a full traditional mdma psychedelic event for 1 to 2 hours. No therapy. Treatment protocol is similar to Ketamine. BPL3 is the headliner because it fits well with existing treatment protocols. The medical community is struggling to define medication-assisted therapy best practices. Someone taking mdma cranks up the neuroplastidity and then hands the reprogramming off to a therapist that has no special training and limited experience. That is a hard pass for me. Getting EMP-1 to mainstream use and profitable is like hiking the PCT compared to BPL-3 which is more like running a marathon.

franker555

I am so confused. PCT released their ER report but theres no EPS to be found anywhere on there. They showed revenue but no eps. Where tf am i supposed to find eps if its not on their report

franker555

Welp im in PCT HEAVY

franker555

Can i get some last minute opinions on PCT. The support its sitting on is so fucking juicy im tempted to buy before ER today

GuessLegitimate2951

That makes sense. I bought into both PCT and Kraken 😂 those are doing pretty well for me. Ill see how it goes tomorrow and look more into the company. Thanks.

DrSeuss1020

Ya still in PCT. I hit my ATH a few months ago but down about 35% from my ATH atm in large part due to the recent tech selloff. Up about 3X total from a couple years ago tho so it’s all relative

sharmoooli

You still in $PCT?? What's your portfolio perf been like? Looking at your history, you have made some good calls.....

mtnrnnr802

Hell yeah dude. I’ve flown into Reno and hitched into Yosemite a few times. Spent some quality time on the PCT/ JMT. I’m probably doing the same this fall but gonna hit the Sierra High Route.

Callejon007

Is the PCT guy still here?

RandomRedditor5689

I looked at PCT options live right now, they are VERY wide so getting a real mid might be problematic and inefficiency in the put-call prices is most likely going to get eaten up with bid/ask , unless there is some axed price in the market. In any case, take a look at something liquid , like SPY options and you will be able to see that in an efficient and liquid market, the prices of puts and calls for the same expiry and strike are "equivalent" when taking into account the intrinsic value and the risk free rate + dividends. This is because you can take a synthetic forward position in any stock by buying the call and selling the put for the same strike and expiry. This is not to say that you could pick up some pennies here or there, but the strategy for trying to systematically find those opportunities is a bit different from what you are trying to achieve I think,

S-n-P500

In your scenario the most you can make is $13 excluding fees in 50 days while tying up $947 + $360, but you are starting with a capital loss of $347. It’s unclear what your thesis is on future price for next 1 1/2 months (high and low expectation). That’s your starting point for determining best option strategy to use. If you just held the stock and it rebounded to $11 in the meantime you could have made $153. PCT is not really the best choice for options because of the widespread and low volume.

HungJurror

Yeah I guess that makes sense. These two actions are identical in profit? A. PUT(sell to open) | PCT | exp 3/20 | strike $6 | prem .20 B. Buy 100 shares at 9.47, then: Call(sell to open) | PCT | exp 3/20 | prem .70 | Strike $9 If the stock falls to $6 I lose big on the put I sold, I’ll get assigned at a good price but the put is worth way more and I’m stuck with it until 3/20 Action B allows me to get out at any time without a loss, but I guess at the end of the day all I’m doing is trying to purchase at a discounted price

BostonCharlie2021

Try PCT. Gaining traction expect big things in 2026.

ihavearoomba

That's so true, I did find plenty a gems in here too like PCT, COPX, GLTO, my beloved APLD and even ultra silly AFJK which I've been day trading the hell off for the longest now. Every now and then the regards really pull off some absolute gems from nowhere lol

itchfen70

Yes. Buy PCT now? Or MP?

Horstov

What’s the next play? PCT?

Fun-Macaron3969

Any news on GUTS today? I am long it. I know some data expected to be released soon. My other two holdings are PCT and AUR.

version-two

Depends on how open looks and how asinine the speech is tomorrow morning .. I'm (planning to) enter/add here: $APLD - April/May calls || $NBIS - June $120C || $SLV - April ATM C's || $GOOG $335C || $PCT 1/27 Leaps || $MRVL April $85C || $ONDS - 1/27 $12C/15C ... And more $POET leaps if I get a pullback. If it's a giant red dong, VIX & watch.

PurposeHaunting4663

PCT, already full port

cumblaster1969

PCT plastic trash or worth it? waiting for pullback and it’s up today 💀

franker555

My entire port is mara and PCT. Having an amazing day.

capvistaview

$PCT up +7% today if it gets over 12.25 it could make a big move

DrSeuss1020

PCT up almost 30% since I posted so not bad! Hoping for some good updates from them in the near term

patcakes

Kraken Robotics, PCT, BFLY, AUR, but honestly, nothing as compelling as ASTS or RKLB were back then that I've seen.

Metacog_Drivel

PCT could squeeze

16twosixes

Valerie Mars, billionaire, appointed to PCT Board in December. 4th generation Mars family fortune, lots of gravitas.

hv876

I had a dream that PCT was above 100

HappyLoveChild27

Watching: Symbiotic, Corteva/Spinco, Enbridge (good dividends), AT&T (long term —- energy via WEC), WEC Energy, Mosaic Company, Intrepid Potash, Lippert Components (LCII), THOR, WeRide Inc, PureCycle Technologies (PCT), PureCycle Corp (PCYO), Barrick Mining, Western Digital Co (WDC)—-started watching WDC in autumn 2025 at $85…it’s at $215 now. Favorite 10-Q/8-K of these are Symbiotic, The Mosaic Company and WEC.

InternationalPhone40

PCT…gym bro brotherhood is calling

ironcladjogging

PCT with 32% short interest 👀

JimmyMcTrade

I got some PCT. I gotta say that it's pure garbage.

Late-Activity-2513

anyone in on PCT?

Carti_2s

I saw your previous post and also the one from your other brother, where he talked about the plant in Ohio and Augusta less than a month ago, and that’s when I started trading $PCT. I started gaining confidence in it and bought at $9. Lately I’ve been reading that there could even be a short squeeze, since short interest has increased the cost for short sellers by up to 16%. Less supply and way too much demand. And with the PIPE warrants that allow investors to buy until March 17, 2026 at $11.50, it feels like they’re actively pushing the price up. Just the day before yesterday they announced they’re opening offices in Bangkok, and today they dropped the news that they’ll be at the CFP final at Hard Rock Stadium. I honestly feel the stock is still cheap. I’m holding about 1,000 shares but I want to increase my position, and since the market is still underestimating Valeria Mars, now feels like the right time to keep buying. Either way, thanks to your post and your brother’s, I’m up 25% in just three weeks. That’s fucking insane, dude. I appreciate you.

LabyrinthLayers

Shoutout to the guy that posted the PCT DD

quietWolves

Blessing the dudes that posted about PCT a few weeks back. Thing is on the cusp of a squeeze.

Snoo-90587

OP only posts about this company are you the ceo or something lol good luck though. Ps: send me a 100k and I’ll yolo for you on PCT

JimmyMcTrade

My $PCT calls are pumping. I love them. They are pure garbage.

No_Privacy_Anymore

I guess you need me to explain things in more detail so you understand. There is a very good reason why "mass balance" chemical recycling is not widespread. It is capital intensive incurs quite a bit of losses between the original plastic waste feedstock and the resulting oil like output which is then blended with other feedstock to make new plastic. Even if the ADUR process worked as well as it is promoter claimed, you are talking about a final product that is expensive to make. In addition, the actual buyers who might consider buying "mass balance" based plastic still have to comply with the packaging requirements of states like New Jersey that require specific % post consumer recycled content and NJ does NOT consider chemical recycling as qualifying. ADUR is so far away from any real commercial sales its not funny. As for PCT being limited to PP #5 plastic, that is a far more efficient approach. For one, there is a MASSIVE amount of PP waste feedstock because there are challenges associated with recycling it. That means the feedstock is cheap. They can sort out what they need and resell the other plastic and other streams to other companies. Designing a factory for a single type of plastic allows you optimize things in a way that is much harder when you are dealing with substantial variation in your feedstock. Of course ADUR wouldn't really be able to speak about that because they are not even close to running a commercial scale facility. I wish them well but they are in for a VERY long journey with a ton of challenges ahead.

Routine-Pizza8362

whats the point? they will produce another raw material and while PCT has limitations in terms of which plastics can be recycled, ADUR as barely any. moreover wtf is that argument who cares about new jersey🤣

DoubleFamous5751

Yo PCT guy, thanks again 🙌 regards like you make this place the casino that it is

michael2334

PCT - they have proven their tech works at scale in 2025. This is the year they ramp up production and shift from a pre-revenue business plan to a legit business

No_Privacy_Anymore

$PCT This will be a breakout year for r/Purecycle

Metacog_Drivel

Best momentum trades right now: ONDS, KRKNF, PCT, OUST, BAER. Enjoy.

DarkOdysseyArts

PCT printed hard yesterday and into today

Mikeyboi337

PCT 🚀🚀

clarkent281

Why PCT mooning today?

BringTheFacts

PCT?

DoubleFamous5751

PCT taking out 10 👀

Metacog_Drivel

PCT making a move

DarkOdysseyArts

PCT printing today

Carti_2s

Fuck off. PCT is downing dude it’s a fucking joke. Let’s we buying more. Shit morning Wednesday https://preview.redd.it/v3kpnngriybg1.jpeg?width=959&format=pjpg&auto=webp&s=2ab2018d682b9b56319e3c680f7b21bc3c876cae

DoubleFamous5751

Last one I liked was PCT, was like 2 weeks ago

dabasedabase

PCT

Academic-Chemistry33

Look at $PCT

Carti_2s

https://preview.redd.it/wb5n5cxf0mbg1.jpeg?width=959&format=pjpg&auto=webp&s=1b188b27aca8037a773c64d5f034ef3e8a1b8c4c PCT is get up and it’s time to buy baby!

Carti_2s

i recommend you investment in PCT (PureCycle Technology). His price right now is so cheap and it’s undervalued even so until today. 2026 promise be a good year for they with excellent returns bud n’ I think is better option than TTWO. GTA VI have very hype but not to good.

Avid_Hiker69

For sure. Thanks for your comment. I would be happy with 4x. In your opinion, what are your thoughts on Daniel Gibson who currently owns 18% of $PCT under Sylebra Capital? I know they have been injecting into $PCT since 2021 but Daniel sounds like a tool based on his tweets. He mentioned that AI is a bubble in 2023...

Carti_2s

I’m a big believer that PCT will be a share with great profits in 2026. Just waiting his 10Q of the last trimester But PCT to Mars bud. LFgggg

version-two

PCT

burner-1234

At least someone has done some work! PVC can be separated via optical sorters or separation tanks - PCT using optical sorters. The Ironton plant has 97%+ PP feed going into it. Denver is an extremely important step that no one seems to appreciate. If this sorting tech wasnt around PE/PET recycling would not even exist, today rPET is 20% of the PET market. Feed stock bales (roughly 60% PP) are 11-15c per pound. Selling post sorted scrap (aluminum, PE/PET, PVC and co products from Ironton co-products bring it to about net 10c per pound). From there it costs about 5c for transport and another 15-30c per pound to run the process depending on energy costs. If you look at LCA analysis and energy needs to run PCT sorting + dissolution vs virgin production you will see on a per pound basis PCT process is actually cheaper than virgin production - once PCT builds larger capacity lines they will actually be cheapest producer of PP (but that is likely a discussion for the future). u/Medical-Shoulder-337 not sure what you are referring to with lawsuit costs? Again, there is a lot here. It has been a long journey for the co but they have solved these issues over the last months/years. It is worth your while to understand what is actually happening here - I'd call up your expert again...

No-Rule9083

There’s a market for most things but it comes down to Cost of Goods Sold (CoGS). I am only just learning about PCT so I’m not weighing in as a bear or bull. I’ll look into the coproducts, thanks!

HVACStack

Any love for PCT purecycle technologies in this thread?

Carti_2s

bud I don't think the price will drop to 8 when the last quarter of the year is about to end. I think it's a good time to enter in 9. PCT to Mars. Me too I’ve shares and opened in 9.10$. It’s time to buyyyyyy

Carti_2s

PCT!! That rocket it will take off bud 🚀

PickleRickleTV

It’s not AI moderation in your case, I think. They shut down any pump and dump schemes. While that may not have been your intention, the activity and posts about and around PCT have spiked suddenly the past few days. I’ve seen mods take down posts about other stocks that happened to. To them, it appears to be a coordinated effort to pump a stock.

14X8000m

It's nice to see that you're building a small, reasonable, entry level position here. Good luck fellow PCT regard.

Carti_2s

$PCT to MARS baby 🚀

Carti_2s

What tfff pal great profit. Now you can do an all-in of $PCT n’ you’ll going so Longg. LFggggg

Xenonstrike

Brand affiliate? You work for PCT?

jmnugent

If ASTS wants to sponsor me,. I'll hike PCT or Appalachian. I'd carry equipment and do signal testing and daily reports etc if they wanted me to.

Gambler_Addict_Pro

Dr Seuss recommended PCT. His picks were good. 

Ok-Surround-5811

PCT

Academic-Chemistry33

In all honesty, I don’t see anything big happening with $PCT anytime soon, I see it more as a long term hold and have a bigger share position. I felt the need to pick these calls up tho when I saw it recovering from that tasty dip 🤤

JimmyMcTrade

Here's my wish list for January: PATH to $25 ONDS to $20 LULU to $225 PCT to $15 [ATRL.TO](http://ATRL.TO) to $115 and a nice booty to play with.

Neither-Cow-410

PureCycle Technologies $PCT concept plant in ironton is in very early stages of commercialization with proctor and gamble, sherwin Williams, mars inc, all very interested in their recycled polypropylene, which is expected to sell for a premium over virgin material. Their solvent method of recycling is novel, no one else is doing it, it’s economically efficient. Second generation facilities are expected to produce polypropylene cheaper than virgin.

Temporary-Equal-774

I did some simple dd after reading this post and reached the same conclusion as your friend. Currently PCT sells their recycled resin at a much higher price than virgin material. Even if they can successfully scale in the future, it's still nearly impossible for them to make it cheaper than virgin material. So no company will consider their product expect those with sustainability mandates. This solely depends on the federal and state policies. Personally I don't think this kind of business model - forcing companies to pay premium for an economically inferior product, is sustainable. Thus I'll sit out for this one

DoubleFamous5751

PCT DD guy might be on to something 🤔

DoubleFamous5751

Regard who posted PCT DD this weekend, I have entered today

Substantial_Word5891

Yes, I think the between mechanical recycling and chemical recycling (encumbents) this perspective is valid. Chemical recycling is incredibly energy intensive and when looking at the value chain, you already need significant investments to ensure feedstock maturation - the combined economics only work if government steps up with tax incentives. Mechanical recycling is sub par. PCT uses dissolution recycling, which is significantly less energy intensive than chemical recycling. It doesn’t break any of the covalent bonds of the plastic compounds. As such it’s a plastic to plastic solution. Which is in effect a drop in replacement for end users. When you combine compounding and additives, the net increase to an end costumer is negligible. IE a 30,000 car costing 31,000 isn’t a deal breaker. Look into dissolution recycling, tons of research has gone into it. And pct is the first company of its kind attempting at this commercialized inflection point. Future builds on roadmap with improve mechanical designs, and throughput. Company has goals to reduce the spread with their R-pp vs Virgin to parity. Check out r/purecycle tons of knowledgeable folk there.

Techters

Me. No presents for Christmas: GNRC, PCT, POET 💩 

14X8000m

Hoping RKLB and PCT moon. RKLB dropping 5% in aftermarket didn't help my optimism.

broke_ugly_dumb

LMAO PCT GUY APPEARED I opened a position yesterday, thanks bros

RunSad429

All good. Thank you for the response. Regarding PCT, is there a specific catalyst you’re waiting for? From your post, it sounds like the company is waiting for the ‘stamp of approval’ that these resin pellets are in fact ‘recycled’ material. Is there a regulatory body that overseas that?

krexfuller

Maybe? I invested a much smaller amount in PCT at the same time that I went in on RKLB. Good thing, right? It has gone nowhere so far.

Academic-Chemistry33

$PCT 35x $15, 3/20 2026 Calls

ErieEric

Alright - totally anecdotal but I randomly have been working with some packaging company’s and they have fits with recycled resins in their thermoforming and ink mold processes. But they have to use them - maybe their customers demand a % reuse in the mix. The problem isn’t the end product integrity, it’s that the regrind/recycled materials don’t play nice with their machines - the down time and scrap is significant. If PCT has something that behaves like virgin resin, but still counts as reuse - I’m on board. Bought 50 premarket and will add if things progress. Good write up by the way.

BigAd1968

Thoughts on PCT?

BigShmokeBuffer

Another PCT bag holder desperately seeking confirmation bias. I won’t give it to you. I will pick this stock up for cheaper later when the market is down and when you’ve sold out of your bags for a big loss. Go back to the PCT subreddit and stop annoying me